24
SOURCE XT Clinical Data
Table 10:
SOURCE XT (High Risk) Baseline Characteristics of the Patients and Echocardiographic Findings
(AT Population)*
Transfemoral
TA/TAo Pooled
Characteristic
(N = 1685)
(N = 995)
Age - yr
82.0 ± 6.5
80.3 ± 6.5
Male sex — no. (%)
600 / 1685 (35.6%)
536 / 995 (53.9%)
STS score
†
8.0 ± 6.8
7.9 ± 6.2
Logistic EuroSCORE
‡
19.8 ± 11.6
21.6 ± 13.7
NYHA class
I/II — no./total no. (%)
377 / 1676 (22.5%)
242 / 992 (24.4%)
III/IV — no./total no. (%)
1299 / 1676 (77.5%)
750 / 992 (75.6%)
Coronary artery disease — no./total no. (%)
667 / 1685 (39.6%)
518 / 995 (52.1%)
Previous myocardial infarction — no./total no. (%)
205 / 1685 (12.2%)
197 / 995 (19.8%)
Previous intervention
CABG — no./total no. (%)
204 / 1685 (12.1%)
226 / 995 (22.7%)
PCI — no./total no. (%)
460 / 1685 (27.3%)
355 / 995 (35.7%)
Balloon aortic valvuloplasty — no./total no. (%)
128 / 1685 (7.6%)
66 / 995 (6.6%)
Cerebral vascular disease — no./total no. (%)
191 / 1685 (11.3%)
143 / 995 (14.4%)
Peripheral vascular disease — no./total no. (%)
248 / 1684 (14.7%)
320 / 995 (32.2%)
COPD
Pulmonary Artery Disease COPD — no./total no. (%)
327 / 1684 (19.4%)
218 / 995 (21.9%)
Pulmonary Artery Disease Oxygen Dependent — no./total no. (%)
31 / 1684 (1.8%)
11 / 995 (1.1%)
Creatinine > 2 mg/dL (177 μmol/liter) — no./total no. (%)
104 / 1681 (6.2%)
114 / 994 (11.5%)
Atrial fibrillation — no./total no.
395 / 1678 (23.5%)
289 / 990 (29.2%)
Permanent pacemaker — no./total no. (%)
170 / 1685 (10.1%)
134 / 995 (13.5%)
Pulmonary hypertension — no./total no. (%)
440 / 1684 (26.1%)
204 / 995 (20.5%)
Frailty
§
— no./total no. (%)
896 / 932 (96.1%)
548 / 579 (94.6%)
Extensively calcified aorta — no./total no. (%)
71 / 1684 (4.2%)
103 / 995 (10.4%)
Chest-wall deformity — no./total no. (%)
18 / 1684 (1.1%)
6 / 995 (0.6%)
Liver disease — no./total no. (%)
52 / 1685 (3.1%)
27 / 995 (2.7%)
Echocardiographic findings
Aortic-valve area — cm
2
0.7 ± 0.21
0.7 ± 0.21
Mean aortic-valve gradient — mmHg
49.2 ± 16.54
45.0 ± 15.43
Mean LVEF — %
55.1 ± 12.48
53.2 ± 12.50
Moderate or severe mitral regurgitation
**
— no./total no. (%)
345 / 1633 (21.1%)
174 / 976 (17.8%)
* Plus–minus values are means ± SD. To convert the value for creatinine to micromoles per liter, multiply by 88.4. AT
denotes as treated population, CABG denotes coronary-artery bypass grafting, COPD chronic obstructive pulmonary
disease, LVEF left ventricular ejection fraction, NYHA New York Heart Association, PCI percutaneous coronary
intervention, and TAVR transcatheter aortic-valve implantation.
†
The Society of Thoracic Surgeons (STS) score measures patient risk at the time of cardiovascular surgery on a scale that
ranges from 0% to 100%, with higher numbers indicating greater risk. An STS score higher than 10% indicates very high
surgical risk.
‡
The logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE), which measures patient risk at the
time of cardiovascular surgery, is calculated with the use of a logistic-regression equation. Scores range from 0% to 100%,
with higher scores indicating greater risk. A logistic EuroSCORE higher than 20% indicates very high surgical risk.
§
Frailty was determined by the surgeons according to prespecified criteria.
** Moderate or severe mitral regurgitation was defined as regurgitation of grade 3+ or higher.